India Stands Firm: No 'Data Exclusivity' in UK-India Trade Pact

India has rejected the UK's demand for a 'data exclusivity' provision in the newly announced free trade agreement, as it seeks to protect its domestic generic drugs industry. This decision aligns with India's objective to support the growth of its significant generic drug export sector.

In a bid to safeguard its burgeoning generic drugs industry, India has rebuffed the United Kingdom's request to incorporate a 'data exclusivity' provision in their recently concluded free trade agreement, announced on May 6.

The UK pushed for this provision during negotiations, aiming to secure exclusive rights over technical data crucial for the pharmaceutical innovators. However, India remains firm on not including it, prioritizing the flourishing of its domestic generic drug industry, which significantly contributes to exports.

This decision mirrors India's earlier stance with the EFTA bloc in March 2023. By standing firm, India continues to ensure the protection and growth of its USD 25 billion generic drug sector.

(With inputs from agencies.)